Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.42 |
| ▸ | AGER | Q15109 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16320283 | 0.76 | KDM4E (0.39) | SMN1; SMN2RAB9ANPC1LMNAALDH1A1 | |
| SCHEMBL19915073 | 0.73 | NPSR1 (0.61) | HPGDSMN1; SMN2RAB9ATSHRNPC1 | |
| SCHEMBL4838809 | 0.72 | CA1 (0.42) | HPGDSMN1; SMN2RAB9ATSHRNPC1 | |
| SCHEMBL28189800 | 0.71 | CA1 (0.41) | HPGDTSHRTP53LMNAALDH1A1 | |
| SCHEMBL7474651 | 0.69 | MAPK1 (0.43) | HPGDSMN1; SMN2RAB9ANPC1TP53 | |
| SCHEMBL2374957 | 0.69 | NPSR1 (0.42) | HPGDSMN1; SMN2RAB9ATSHRNPC1 | |
| SCHEMBL20931339 | 0.69 | KDM4E (0.54) | HPGDSMN1; SMN2RAB9ATSHRNPC1 | |
| SCHEMBL1646836 | 0.68 | LMNA (0.55) | HPGDSMN1; SMN2RAB9ATSHRNPC1 | |
| SCHEMBL2469196 | 0.68 | PDE4A (0.40) | TSHRALDH1A1PDGFRBPDGFRAALOX15 | |
| SCHEMBL7476821 | 0.67 | SMN1; SMN2 (0.42) | SMN1; SMN2RAB9ATSHRNPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2544684-B1 | 4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES USEFUL AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-1 (DPP-1) | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-24 | — | — | EP | disclosed |
| US-20110224209-A1 | 4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES USEFUL AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-1 (DPP-1) | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224209-A1 | 4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES USEFUL AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-1 (DPP-1) | DPP4, DPP3, DPP7 | HPGD 2257/4885SMN1; SMN2 2286/4885RAB9A 3028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.